Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Short term Debt (2022)

Denali Therapeutics (DNLI) has disclosed Short term Debt for 1 consecutive years, with $4.4 million as the latest value for Q4 2022.

  • Quarterly Short term Debt changed N/A to $4.4 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $4.4 million through Dec 2022, changed N/A year-over-year, with the annual reading at $4.4 million for FY2022, N/A changed from the prior year.
  • Short term Debt for Q4 2022 was $4.4 million at Denali Therapeutics, up from $1.4 million in the prior quarter.
  • The five-year high for Short term Debt was $4.4 million in Q4 2022, with the low at $1.4 million in Q3 2022.